Literature DB >> 22476035

How to characterise a solid renal mass: a new classification proposal for a simplified approach.

O Hélénon1, D Eiss, P Debrito, S Merran, J-M Correas.   

Abstract

The reference method for characterising a solid renal mass is computed tomography. MRI and ultrasound can provide useful diagnostic information for characterising masses the cystic or solid nature of which it is not possible to determine from data from the CT scan. For characterising a solid mass, only MRI can replace the CT scan in most cases. Once a mass has been shown to be solid and vascularised and not occurring in a context suggesting an inflammatory pseudotumour, it can be put, using CT, into one of the four categories of the classification that we propose: pseudotumoral dysmorphisms (type 1); typical high-fat angiomyolipomas (type 2); suspect indeterminate tumours (type 3); typically malignant tumours (type 4).
Copyright © 2012. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Year:  2012        PMID: 22476035     DOI: 10.1016/j.diii.2012.01.016

Source DB:  PubMed          Journal:  Diagn Interv Imaging        ISSN: 2211-5684            Impact factor:   4.026


  4 in total

1.  EXPERIENCE WITH MANAGING SOLID KIDNEY TUMOURS IN COTONOU, BENIN REPUBLIC.

Authors:  Dgj Avakoudjo; P P Hounnasso; M T Traore; G Natchagandé; A K Pare; R Tore-Sanni; M M Agounkpé; S Ouédraogo; F Soumanou; A Gouissi
Journal:  J West Afr Coll Surg       Date:  2014 Oct-Dec

2.  Solid renal masses in adults.

Authors:  Mahesh Kumar Mittal; Binit Sureka
Journal:  Indian J Radiol Imaging       Date:  2016 Oct-Dec

Review 3.  Immune consequences of anti-angiogenic therapyin renal cell carcinoma.

Authors:  Klaudia K Brodaczewska; Cezary Szczylik; Claudine Kieda
Journal:  Contemp Oncol (Pozn)       Date:  2018-03-05

4.  Study of 320-slice dynamic volume CT perfusion in different pathologic types of kidney tumor: preliminary results.

Authors:  Chao Chen; Qi Liu; Qiang Hao; Bing Xu; Chao Ma; Huojun Zhang; Qianjin Shen; Jianping Lu
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.